Cramer, Paula, Eichhorst, Barbara, Reinhardt, Hans Christian and Hallek, Michael (2016). Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Pract. Res. Clin. Haematol., 29 (1). S. 111 - 122. OXFORD: ELSEVIER SCI LTD. ISSN 1532-1924
Full text not available from this repository.Abstract
Given the current dynamics in the development of novel agents for CLL therapy, the task to find optimal, non-toxic combinations has become the primary goal. This article gives an update of the most interesting novel drugs. The strategy of the German CLL Study Group to use these agents in combinations is described in detail, highlighting the strategy and first results of a recently started series of phase II combination trials, the BXX series using agents such as bendamustine, idelalisib, ibrutinib, obinutuzumab, ofatumumab and venetoclax. (C) 2016 Published by Elsevier Ltd.
Item Type: | Journal Article | ||||||||||||||||||||
Creators: |
|
||||||||||||||||||||
URN: | urn:nbn:de:hbz:38-281851 | ||||||||||||||||||||
DOI: | 10.1016/j.beha.2016.08.010 | ||||||||||||||||||||
Journal or Publication Title: | Best Pract. Res. Clin. Haematol. | ||||||||||||||||||||
Volume: | 29 | ||||||||||||||||||||
Number: | 1 | ||||||||||||||||||||
Page Range: | S. 111 - 122 | ||||||||||||||||||||
Date: | 2016 | ||||||||||||||||||||
Publisher: | ELSEVIER SCI LTD | ||||||||||||||||||||
Place of Publication: | OXFORD | ||||||||||||||||||||
ISSN: | 1532-1924 | ||||||||||||||||||||
Language: | English | ||||||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||||||
Subjects: | no entry | ||||||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||||||
Refereed: | Yes | ||||||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/28185 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |